Our data are consistent with the preferential use of pyruvate for the T2D-associated metabolism that fuels the inflammation characteristic of CD4+ T-cells from people with T2D, and fundamentally differs from fasting-induced changes in cell function. Here, CD4 is linked to type 2 diabetes mellitus.